Chartwell Investment Partners’s Axsome Therapeutics AXSM Stock Holding History

Chartwell Investment Partners’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$522K	Buy	5,808 +45	+0.8%	+$3.93K	0.02%	398
2024 Q2	$464K	Sell	5,763 -943	-14%	-$69.8K	0.02%	398
2024 Q1	$536K	Buy	+6,706	New	+$563K	0.02%	396
2021 Q3	–	Sell	-16,261	Closed	-$1.1M	–	430
2021 Q2	$1.1M	Buy	16,261 +146	+0.9%	+$8.76K	0.03%	367
2021 Q1	$912K	Sell	16,115 -865	-5%	-$60.8K	0.03%	366
2020 Q4	$1.38M	Buy	16,980 +9,433	+125%	+$705K	0.04%	328
2020 Q3	$538K	Hold	7,547	–	–	0.02%	389
2020 Q2	$621K	Sell	7,547 -2,765	-27%	-$213K	0.02%	366
2020 Q1	$607K	Sell	10,312 -13,027	-56%	-$1.06M	0.03%	354
2019 Q4	$2.41M	Buy	+23,339	New	+$943K	0.08%	262

Other funds holding AXSM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Chartwell Investment Partners's AXSM Position: Q3 2024 in Review

Chartwell Investment Partners increased its Axsome Therapeutics (AXSM) stake by 0.78% in Q3 2024, buying an estimated $3.93K and bringing the position to 5,808 shares worth $522K. The position accounts for 0.02% of the portfolio, ranked #398.

Chartwell Investment Partners first reported a position in AXSM in Q4 2019 and has held it in 10 quarters since. The position peaked at $2.41M in Q4 2019. 279 funds tracked by Wall St. Rank hold AXSM as of Q3 2024.

Chartwell Investment Partners held 5,808 shares of Axsome Therapeutics worth $522K as of Q3 2024.
Chartwell Investment Partners bought 45 Axsome Therapeutics shares in Q3 2024, an estimated $3.93K.
Axsome Therapeutics made up 0.02% of Chartwell Investment Partners's portfolio in Q3 2024, its #398 holding.
Chartwell Investment Partners first reported a position in Axsome Therapeutics in Q4 2019 and has held it in 10 quarters since.
Chartwell Investment Partners's Axsome Therapeutics position peaked at $2.41M in Q4 2019.
279 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2024.

Based on Chartwell Investment Partners's 13F filing for Q3 2024, filed 4 Nov 2024.